The Future of
Drug Discovery is Here.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Who We Are
Duis irure dolor reprehenderit
in voluptate velit esse cillum
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Quis ipsum suspendisse ultrices gravida. Risus commodo viverra maecenas accumsan lacus vel facilisis. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Quis ipsum suspendisse.
What We Do
Duis irure dolor reprehenderit
in voluptate velit esse cillum
High-Throughput Screening
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
High-Throughput Screening
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
High-Throughput Screening
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Client Outcomes
Duis irure dolor reprehenderit
in voluptate velit esse cillum
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Quis ipsum suspendisse ultrices gravida. Risus commodo viverra maecenas accumsan lacus vel facilisis. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Quis ipsum suspendisse.
News
Duis irure dolor reprehenderit
in voluptate velit esse cillum
Axcelead DDP and Superluminal Announce the Intent to Collaborate on Drug Discovery Targeting Specific Molecular Mechanisms, continuing a productive relationship
Kanagawa, Japan and Boston, MA, USA – Jun 23, 2025– Axcelead Drug Discovery Partners, Inc. (HQ: Fujisawa,...
LOTTE BIOLOGICS, Axcelead Drug Discovery Partners, Inc., and Kanaph Therapeutics Inc. Sign 3-Way MOU to Develop ADC Toolbox
- Exploring expansion of ADC services through synergy in ADC modality business via trilateral agreement - Aims...
The results of joint research with Luxna Biotec, Inc published in “Nucleic Acid Therapeutics”
Hepatotoxicity Reduction Profiles of Antisense Oligonucleotides Containing Amido-Bridged Nucleic Acid and 2′-O,4′-C-Spirocyclopropylene Bridged Nucleic Acid Publication Amide-bridged...